Theranostic PET for Target Validation and Tumor Detection

Recruiting now

Conditions studied: Solid Malignancies

In brief

Patients are referred for theranostic PET using different tracers as part of clinical routine for tumor staging, re-staging, and therapy planning to our department. The aim of this study is to collect data on the expression of target molecules/receptors, proportion of PET positive tumor regions, positive predictive value, detection rate, reproducibility, and impact on clinical management of theranostic PET/CT or PET/MRI using novel theranostic PET tracers or other established PET tracers that are performed in theranostic concepts on patients receiving this imaging modality as part of clinical standard both at initial diagnosis and restaging before treatment decisions. Primary Endpoint: Association between PET uptake intensity in theranostic PET and histopathologic expression of the respective molecular target.

Key facts

Study ID

NCT07664410

Run by

University Hospital, Essen

People needed

2000

Starts

2025-09-23

Expected to finish

2035-09-23

Last updated by the study team

2026-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• PET imaging with a theranostic PET tracer scheduled for staging or restaging of tumor types as part of clinical routine
• Age ≥ 18 years

You may not qualify if…

• Patient cannot give consent for the study
• Patient cannot lie flat or tolerate PET imaging
• Unwillingness or inability to comply with study and follow-up procedures
• Condition of patient which is critical to participate in this study in the discretion of the investigators
• Pregnant, lactating, or breast-feeding women

Where it is running

• University Hospital Essen — Essen, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.